WO1992015695A1 - Process for the c-terminal modification of peptides having a c_terminal penultimate proline residue - Google Patents
Process for the c-terminal modification of peptides having a c_terminal penultimate proline residue Download PDFInfo
- Publication number
- WO1992015695A1 WO1992015695A1 PCT/DK1992/000064 DK9200064W WO9215695A1 WO 1992015695 A1 WO1992015695 A1 WO 1992015695A1 DK 9200064 W DK9200064 W DK 9200064W WO 9215695 A1 WO9215695 A1 WO 9215695A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- peptide
- pro
- reaction
- thr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000008569 process Effects 0.000 title claims abstract description 39
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 23
- 238000011191 terminal modification Methods 0.000 title description 6
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 title description 3
- 108010059081 Cathepsin A Proteins 0.000 claims abstract description 61
- 102000005572 Cathepsin A Human genes 0.000 claims abstract description 61
- 239000000758 substrate Substances 0.000 claims abstract description 56
- 102000004190 Enzymes Human genes 0.000 claims abstract description 34
- 108090000790 Enzymes Proteins 0.000 claims abstract description 33
- 239000012038 nucleophile Substances 0.000 claims abstract description 33
- 150000001413 amino acids Chemical group 0.000 claims abstract description 27
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims abstract description 24
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims abstract description 24
- 102000055006 Calcitonin Human genes 0.000 claims abstract description 17
- 108060001064 Calcitonin Proteins 0.000 claims abstract description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 16
- 229960004015 calcitonin Drugs 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 12
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 230000000813 microbial effect Effects 0.000 claims abstract description 6
- 235000013311 vegetables Nutrition 0.000 claims abstract description 6
- 239000006185 dispersion Substances 0.000 claims abstract description 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 108091005601 modified peptides Proteins 0.000 claims abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 91
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 78
- 238000006243 chemical reaction Methods 0.000 claims description 74
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 64
- 229910021529 ammonia Inorganic materials 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 31
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 25
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 150000001408 amides Chemical class 0.000 claims description 24
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- -1 benzylsuccinyl groups Chemical group 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 108010068072 salmon calcitonin Proteins 0.000 claims description 10
- 239000012429 reaction media Substances 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000010979 pH adjustment Methods 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 241000972773 Aulopiformes Species 0.000 claims description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000001879 gelation Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000002952 polymeric resin Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 235000019515 salmon Nutrition 0.000 claims description 2
- 229920003002 synthetic resin Polymers 0.000 claims description 2
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 abstract description 30
- 230000009435 amidation Effects 0.000 abstract description 29
- 229940045644 human calcitonin Drugs 0.000 abstract description 23
- 210000004899 c-terminal region Anatomy 0.000 abstract description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 101150009274 nhr-1 gene Proteins 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 239000006227 byproduct Substances 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 20
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 16
- 229960000583 acetic acid Drugs 0.000 description 16
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 16
- 230000007062 hydrolysis Effects 0.000 description 14
- 238000006460 hydrolysis reaction Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 9
- 239000012362 glacial acetic acid Substances 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 7
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 7
- 101710142969 Somatoliberin Proteins 0.000 description 7
- 108010059841 serine carboxypeptidase Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010004237 Glycine oxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical group NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010005991 Pork Regular Insulin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940066758 endopeptidases Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- KACAMSDOZKVKNP-LURJTMIESA-N (2s)-n-ethylpyrrolidine-2-carboxamide Chemical group CCNC(=O)[C@@H]1CCCN1 KACAMSDOZKVKNP-LURJTMIESA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000228251 Aspergillus phoenicis Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 101000741396 Chlamydia muridarum (strain MoPn / Nigg) Probable oxidoreductase TC_0900 Proteins 0.000 description 1
- 101000741399 Chlamydia pneumoniae Probable oxidoreductase CPn_0761/CP_1111/CPj0761/CpB0789 Proteins 0.000 description 1
- 101000741400 Chlamydia trachomatis (strain D/UW-3/Cx) Probable oxidoreductase CT_610 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 241001561395 Citrus natsudaidai Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 240000002024 Gossypium herbaceum Species 0.000 description 1
- 235000004341 Gossypium herbaceum Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 1
- 241000228129 Penicillium janthinellum Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZKQOUHVVXABNDG-IUCAKERBSA-N Pro-Leu Chemical group CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 ZKQOUHVVXABNDG-IUCAKERBSA-N 0.000 description 1
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 1
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 230000001365 aminolytic effect Effects 0.000 description 1
- RQIVQWNPDBWTJG-WCCKRBBISA-N aminourea;(2s)-pyrrolidine-2-carboxylic acid Chemical group NNC(N)=O.OC(=O)[C@@H]1CCCN1 RQIVQWNPDBWTJG-WCCKRBBISA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- CTZZSWNVVFTJRN-UHFFFAOYSA-N benzyl n-(1-amino-1-oxopropan-2-yl)carbamate Chemical compound NC(=O)C(C)NC(=O)OCC1=CC=CC=C1 CTZZSWNVVFTJRN-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- KFGRVLINLVVMJA-MITYVQBRSA-N chembl440262 Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 KFGRVLINLVVMJA-MITYVQBRSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- RJQRCOMHVBLQIH-UHFFFAOYSA-N pentane-1-sulfonic acid Chemical compound CCCCCS(O)(=O)=O RJQRCOMHVBLQIH-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 108010056001 somatotropin releasing hormone (1-29) Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 238000005924 transacylation reaction Methods 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
- C07K14/5855—Calcitonins at least 1 amino acid in D-form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/17—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced ascorbate as one donor, and incorporation of one atom of oxygen (1.14.17)
- C12Y114/17003—Peptidylglycine monooxygenase (1.14.17.3)
Definitions
- the present invention relates to a process for the C- terminal modification of peptides, especially for the preparation of peptides having a C-terminal proline amide or N-substituted amide, e.g. human or salmon calcitonin or their analogs.
- Tanaka et al an ⁇ -amidating enzyme from the skin of Xenopus laevis (a frog) is described. Tanaka et al have produced this enzyme biosynthetically, but its ⁇ -amidating activity is also conditioned by the presence of C-terminal Gly.
- Amidation may also by achieved by protease-catalysed condensation reactions using an amino acid amide or peptide amide as nucleophile.
- the yields of condensation reactions are generally low even in the presence of organic solvents unless the product precipitates in the reaction mixture and this is often not the case with long peptides.
- the precursor peptide may exhibit poor solubility in such media.
- serine or thiol- protease catalysed transpeptidation reactions may be carried out in high yield but it is a prerequisite that the enzyme exhibits specificity for a peptide bond close to the C-terminus. Endopeptidases are not generally suitable since they usually will cleave at other positions in the peptide chain as well.
- Serine carboxypeptidases exhibit strict specificity for the C- terminal peptide bond and are able to catalyse the exchange of the C-terminal amino acid with an amino acid amide, added to the reaction medium to compete as nucleo- phile with water.
- carboxypeptidase Y (CPD-Y) from yeast.
- Ref. 3 compared the reactivity of various nucleophiles in the exchanges of C-terminal amino acid residues in peptides, and i.a. concluded that ammonia was an applicable nucleophile in transacylation reactions in a manner equivalent to the above-mentioned use of amino acids H-B-NH-.
- Z-Ala-Ala-OH was reacted with H-Gly- NH 2 and with NH « resulting in the formation of Z-Ala-Gly- H 2 and Z-Ala-NH 2 in coupling yields of 100% and 75%, respectively.
- the reaction with H-Gly-OMe also lead to the formation of Z-Ala-Gly-OMe in a yield of 75%.
- ammonia was an applicable nucleophile in C-terminal modification of peptides along with amino acid amides and amino acid esters.
- GRF' denominates the native GRF(1-26) sequence or analogs thereof including GRF(n-26) fragments , where n is from 1 to 8, and X is an uncharged hydrophilic acyclic a- amino carboxylic acid residue having the side chain of at least the size of a methyl group, is reacted with H-Arg- NH 2 as nucleophile component in the presence of an L- specific serine or thiolcarboxypeptidase enzyme from yeast or of animal, vegetable or other microbial origin in an aqueous solution or dispersion having a pH of from 6 to 9, and if necessary the desired N-terminal (l-(n-l)) fragment is coupled chemically or enzymatically.
- Preferred amino acids X are Ala, Thr, Ser, Asn or Gin.
- the process is not always sufficiently selective and necessitates purification procedures in order to remove products of various side reactions in particular when longer peptides are used, in which case the optimal reaction conditions for suppressing the side reactions are difficult to establish.
- Tamaoki obtained S-sulfonated human calcitonin amide in a yield of 24.7%, leaving 57% unreacted substrate and 17.2% non-amidated side products.
- the S-sulfonated calcitonin was reduced with glutathione to give a mature human calcitonin, but no yield is stated.
- Tamaoki patents which are incorporated by reference disclose a process for the pre ⁇ paration of a peptide having a C-terminal proline amide, which comprises reacting in aqueous solution a peptide substrate having C-terminal Pro-Leu, Pro-lie, Pro-Val or Pro-Phe with carboxypeptidase Y in the presence of ammonia.
- the present invention is based on the surprising finding that in peptides of the above type, which may serve as models for i.a. Calcitonins, a different group of amino acid residues is able to act as good leaving groups in carboxypeptidase catalyzed reactions with ammonia, hydrazine or substituted derivatives thereof, ensuring both speediness and high yields, usually far superior to the ones reported in the above-mentioned Tamaoki patent.
- the invention relates to a process for the preparation of C-terminally modified peptides of the general formula
- R is selected from hydrogen, hydroxy, C.,-Cg alkyl, hydroxy C-_, alkyl, C fi _ q aralkyl or R is a group NHR.., wherein R. is hydrogen, C._ 6 aralkyl, Cg_ g aralkyl or a group C0-R 2 , wherein R 2 is selected from H 2 >* ._g alkyl and C ft g aralkyl.
- ft alkyl encompasses straight chain or branched alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl tert.butyl, pentyl and hexyl.
- a preferred alkyl group is ethyl.
- C fi _ q aralkyl encompasses e.g. phenyl-C., alkyl, e.g. benzyl, phenylethyl and phenyl rop l.
- alkyl and aralkyl groups may be substituted with one or more inert substituents, e.g. halogen (F, Cl, Br, I), hydroxy or nitro.
- substituents e.g. halogen (F, Cl, Br, I), hydroxy or nitro.
- X is an amino acid having an uncharged or positively charged side chain comprising at least two carbon atoms and further comprising at least one hetero atom selected from N, 0 and S, with a nucleophile component NH ⁇ -R, wherein R has the above meaning in the presence of an L-specific serine or thiolcarboxypeptidase enzyme from yeast or of animal, vegetable or other microbial origin in an aqueous solution or dispersion having a pH of from 7.5 to 10, and if desired converting a reaction product wherein R is different from hydrogen into a peptide amide.
- R NHC0R 2
- R 2 NH 2 is semicarbazide.
- the applicable group of amino acid leaving groups X spans a wide range of hydrophilicity - from the hydrophobic tryptophan and tyrosine over methionine and its protected derivatives, e.g. sulphone, Met(o), histidine and threonine to the hydrophilic glutamine, asparagine, arginine and lysine using the scale of Hopp & Woods (Ref 13) .
- They share the common structural property of having large (at least C ) side chains, which carry at least one hetero atom chosen among N, 0 and S, said side chains being uncharged or positively charged.
- the process of the invention is suitable for the production of various peptide hormones of the calcitonin type, e.g. human calcitonin having the amino acid sequence:
- a particularly interesting calcitonin having a 20 times greater potency is salmon calcitonin having the amino acid sequence:
- calcitonin from other natural species e.g. eel, chicken, ovine, bovine, porcine and murine calcitonin may be prepared by the process according to the invention.
- hydrazine is used as nucleophile
- the process may be used to produce the corresponding hydrazides, e.g. calcitonin hydrazides.
- it is desired to convert these further by chemical methods, e.g. the azide method it is necessary first to protect N-terminal and possible side chain amino groups in the substrate, by e.g. Boc, before the reaction.
- the protected azide may then be reacted with ammonia to form a protected peptide amide, from which the protective groups may be removed in a manner known per se to form the desired peptide amide, e.g. calcitonin.
- compounds containing a C-terminal proline N-ethyl amide or proline semicarbazide may be prepared according to the process.
- peptides containing these groups of biological interest are e.g. the nonapeptide Luteinizing Hormone Releasing Hormone analogue drugs, Leuprolide®, see GB patent No. 1.434.694, and Buserelin, see US patent No. 4.263.282, having C-terminal Pro-NEt and Goserelin, see US patent No. 4.100.274, having C-terminal Pro-SEM.
- the applicable carboxypeptidases in the process of the invention are L-specific serine or thiol carboxy- peptidases.
- Such enzymes can be produced by yeast fungi, or they may be of animal, vegetable or other microbial origin.
- a particularly expedient enzyme is carboxypeptidase Y from yeast fungi (CPD-Y).
- CPD-Y carboxypeptidase Y from yeast fungi
- This enzyme is described in the earlier patents i.a. with reference to Johansen et al (Ref. 10) who developed a particularly expedient purifica ⁇ tion method by affinity chromatography on an affinity resin comprising a polymeric resin matrix with coupled benzylsuccinyl s.
- CPD-Y which is a serine enzyme is available in large amounts and displays relatively great stability. Further details are given in Ref. 1.
- the native CPD-Y is a well characterized serine carboxypeptidase. A comparison with other such carboxypeptidases is given in Ref. 7. These were also from other sources than yeast or genetically or chemically modified types.
- Another CPD-Y homologous serine carboxypeptidase from yeast, KEX 1 is described in Ref. 14 and further characterized in Ref. 15. A combination of chemical and genetic modification of a yeast carboxypeptidase is described in Ref. 16.
- CPD-Y is easily isolated from baker's yeast after autolysis (Ref. 10) or from the medium of genetically manipulated yeast cells (Ref. 11) as applied in example 18.
- This enzyme has a different glycosylation and molecular weight, but has proved to be equally useful in the native form. The cost of the enzyme is rather low and the procedure described here therefore seems to be a valuable alternative to the use of the much more rare glycine oxidase.
- CPD-Y which is the preferred enzyme at present
- the process of the invention is feasible with other carboxypeptidases from other sources than yeast, such as those listed in the following survey:
- Carboxypeptidases W from Wheat bran Carboxypeptidases from Germinating cotton plants Tomatoes Watermelons Bromelain(pineapple)powder
- the process of the invention may be carried out at pH 7.5 to 10.0, preferably at pH 8.5 to 9.5, most preferably from 9.0 to 9.5. Accordingly, it is necessary for the enzyme to have sufficient stability in alkaline media during the reaction period.
- the preferred pH-value which is often within a very narrow range, depends upon the enzyme used and the substrate employed. For CPD-Y, a favourable pH for most substrates is about 9.2.
- the preferred agents for pH-adjustment in starting solutions containing NH ⁇ are low molecular carboxylic acid, preferably acetic acid or formic acid and good results have also been obtained using some ammonium salts, e.g. H 4 N0 3 .
- organic solvents are dimethyl formamide and dimethyl sulfoxide, but also alkanols, e.g. methanol and ethanol, glycols, e.g. ethylene glycol or polyethylene glycols, triethylene glycol dimethyl ether, glycerol, alkanoic acids, e.g. acetic acid, tetra- hydrofurane, dioxane and dimethoxyethane may be used.
- alkanoic acids e.g. acetic acid, tetra- hydrofurane, dioxane and dimethoxyethane
- acetic acid e.g. acetic acid
- tetra- hydrofurane dioxane and dimethoxyethane
- dimethoxyethane may be used.
- composition of the reaction medium depends particularly upon the solubility of the reaction components and the reaction products involved and upon the stability of the enzyme. These can be affected by addition of urea and/or detergents. Examples are anionic, e.g. pentanesulphonic acid, zwitterionic, e.g CHAPSO, nonionic, e.g. Brij 35 or Tween 20 and cationic, e.g. guanidinium hydrochloride.
- Stabilization of the enzyme might also be brought about by addition of carbohydrates, e.g. mannitol or proteins, e.g. BSA.
- the reaction medium may also comprise a component that renders the enzyme insoluble, but retains a considerable part of the enzyme activity, such as an ion exchanger resin.
- the enzyme may be immobilized in known manner, e.g. by bonding to a matrix, such as a cross-linked dextran or agarose, or to a silica, polyamide or cellulose, or by encapsulating in polyacrylamide, alginates or fibres.
- the enzyme may be modified by chemical means to improve its stability or enzymatic properties.
- a chelating agent e.g. EDTA
- the medium preferably contains a gelation inhibiting agent, e.g. guanidium hydrochloride.
- concentration of the two participants in the reaction may vary within wide limits, as explained below.
- a preferred starting concentration for the peptide substrate is 0.1-5.0 mM, preferably 0.2-1.0 mM, in particular about 0.5 mM, and when the nucleophile is ammonia, it is preferably added as a saturated solution or on liquid form, the concentration is 4.0 to 12.0 M, preferably 4.3 - 9.7 M, in particular 5 - 8 M. This is in contrast to Tamaoki, who only used 4.5 M solution and claimed this to be optimal.
- nucleophiles e.g. benzyl amine
- concentrations of 1.0 to 4.0 M, preferably 2.0 to 3.0 M are used.
- the reaction product e.g. a hydrazide
- the enzyme activity may vary as well, but for CPD-Y the concentration is 5 - 50 urn, preferably 5 - 20 um. The most advantageous activity depends i.a. on the substrate chain and concentration, the nucleophile concentration, the reaction time, the reaction temperature, the pH, and the presence of organic solvents and/or salts.
- the reaction temperature is 20 ⁇ to 40°C.
- An appropriate temperature will usually be about 33° to 39°C, preferably about 37°C, taking into account due consideration for enzyme activity and stability.
- reaction time which depends very much upon the above-mentioned reaction parameters, especially the enzyme concentration.
- the standard reaction time in the process of the invention is about 1 - 5 hours.
- the reaction is preferably carried out in closed vessels at a pressure of 1 - 3 bar, preferably 1 - 2 bar.
- amino acids amino acid derivatives and peptides are according to Guidelines of the IUPAC-IUB Commission on Biochemical Nomenclature and the amino acids are on L-form unless otherwise stipulated.
- HOAc acetic acid
- Bz N-benzoyl
- Boc tert.butyloxycarbonyl
- DMF N,N-dimethylformamide
- EDTA ethylene diamine tetraacetic acid
- GRF growth hormone releasing factor
- HPLC high performance liquid chromatography
- SEM semicarbazide
- TFA trifluoroacetic acid
- TGME triethylene glycol dimethyl ether
- THF tetrahydrofuran
- Z carbobenzoxy
- CHAPSO 3-[(3-cholamidopropyl)- dimethylammonio]-2-hydroxy-l-propane-sulfonate.
- Tripeptides of formula Z-Thr-Pro-X-OH and Z-Ala-Pro-X-OH served as short model substrates for salmon and human calcitonin, respectively.
- Substrates of formula: H-Leu- His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly- Thr-Pro-X-OH served as longer model substrates for salmon calcitonin, corresponding to residues 16 - 32 elongated by X, and henceforth referred to as SAL (16-32)-X.
- SAL (16-32)-X These substrates were obtained by chemical synthesis, by employing liquid and solid phase methods at conventional state of the art level, e.g. as described in appln.
- human calcitonin elongated by one amino acid residue can be obtained by an enzymatic coupling of the free amino acid to the corresponding calcitonin methyl ester using CPD-Y catalysis in aqueous medium (see example 13 below) or by standard solid phase methods followed by formation of the disulfide bridge by cyclization.
- CPD-Y catalysis in aqueous medium see example 13 below
- standard solid phase methods followed by formation of the disulfide bridge by cyclization.
- Met-sulfone substrates were obtained by oxidizing the corresponding methionine substrates e.g. by treatment with hydrogen peroxide.
- Reaction monitoring, product identification and determina ⁇ tion of product yield were performed by means of reverse phase HPLC (Waters 6000 A pumps, automated gradient controller, UK 6 injector) on a C lg NOVA PAK column (Waters, RCM) using suitable gradients of elution systems containing 50 mM triethylammonium phosphate, pH 3.0 or 7.0 from 0% to 80% acetonitrile with a flow of 2 ml/min. Elution was monitored by means of a UV detector (Waters 480) at 230 nm, 254 nm or 278 nm.
- Concentrated ammonia stock solutions were made to form the bulk of the reaction media. Normally at room temperature and at atmosphere pressure of around 1 bar, they were made basically in either of the two ways: either from a concentrated solution of ammonia in water which was mixed with a concentrated or aqueous acid solution or from an ammonium salt which following dissolution in water was mixed with a solid alkali base. Following cooling to room temperature and if necessary dilution by water pH was adjusted using the relevant acid or base. Thus 10 ml of
- 25% aqueous ammonia mixed with either 6.5 ml of glacial acetic acid (HOAc) or 3.7 ml of concentrated formic acid yields solution of 8 M and 10 M ammonia/ammonium concentrations when adjusted to pH 9.2 with concentrated acid, and likewise at the same pH a 4.5 M ammonia/ammonium solution may be obtained by mixing about 26.7 g NH.C1 and 8.1 g NaOH in 100 ml water. Ammonia concentrations are later corrected for decreases as a result of the addition of other solvents, reactants or additives.
- RATIO is calculated from the following formula: 100*YIELD
- the initial substrate is often listed in the examples as a core peptide named PEPTIDE with a separate leaving group listed as LEAVING and the initial substrate concentration as CPEPTIDE.
- the glass flask was placed in a stirred water bath thermostated at 37°C and following the addition of 0.78 ml of a 0.3 mM solution of Carboxy ⁇ peptidase Y to initiate the reaction, the flask was sealed with a plastic screw-cap lid and left in the wa ⁇ ter bath for 75 minutes, after which HPLC showed 76% of the amidated Z-Thr-Pro-NH 2 product, 20% of the hydro- lysis byproduct Z-Thr-Pro-OH and 4% remaining substrate.
- R designates the salmon calcitonin 16-30 sequence.
- R designates the salmon calcitonin 16-30 sequence.
- NE Native Extracted CPD-Y prepared and purified according to
- CPD-Y catalyzed amidation of ZAlaProThr-OH in ammonia/ammonium mixtures pH-adjusted with acetic acida) and further containing various anionic and nonionic detergents at 0.5% (w/v).
- CPD-Y catalyzed amidation of ZAlaProTyr-OH in ammonia/ammonium mixtures pH-adjusted with acetic acida) and further containing various additives.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4505933A JPH06504676A (en) | 1991-03-01 | 1992-03-02 | Method for modifying the C-terminus of a peptide having a proline residue at the second position from the C-terminus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK0373/91 | 1991-03-01 | ||
DK37391A DK37391D0 (en) | 1991-03-01 | 1991-03-01 | ENZYMATIC PROCEDURE FOR C-TERMINAL AMIDATION OF PEPTIDES AND INTERMEDIATES FOR USE BY THE PROCEDURE |
DK0676/91 | 1991-04-15 | ||
DK67691A DK67691D0 (en) | 1991-03-01 | 1991-04-15 | ENZYMATIC PROCEDURE FOR C-TERMINAL MODIFICATION OF PEPTIDES AND INTERMEDIATES FOR USE BY THE PROCEDURE |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992015695A1 true WO1992015695A1 (en) | 1992-09-17 |
Family
ID=26063876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1992/000064 WO1992015695A1 (en) | 1991-03-01 | 1992-03-02 | Process for the c-terminal modification of peptides having a c_terminal penultimate proline residue |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0573540A1 (en) |
JP (1) | JPH06504676A (en) |
AU (1) | AU1374992A (en) |
CA (1) | CA2101074A1 (en) |
DK (1) | DK67691D0 (en) |
IE (1) | IE920664A1 (en) |
WO (1) | WO1992015695A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10047857A1 (en) * | 2000-09-27 | 2002-04-18 | Univ Leipzig | Process for the selective biocatalytic modification of peptides and proteins |
US10053491B2 (en) | 2013-11-05 | 2018-08-21 | Ajinomoto Co., Inc. | Method for producing peptide hydrazide, peptide amide, and peptide thioester |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0197794A2 (en) * | 1985-04-08 | 1986-10-15 | Sankyo Company Limited | Preparation of peptides with C-terminal proline amide |
US4652627A (en) * | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
US4687839A (en) * | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
EP0308067A2 (en) * | 1987-08-14 | 1989-03-22 | Unigene Laboratories Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
WO1990008194A1 (en) * | 1989-01-17 | 1990-07-26 | Suntory Limited | PROCESS FOR PRODUCTION OF C-TERMINAL α-AMIDATED PEPTIDE |
-
1991
- 1991-04-15 DK DK67691A patent/DK67691D0/en not_active Application Discontinuation
-
1992
- 1992-03-02 IE IE920664A patent/IE920664A1/en not_active Application Discontinuation
- 1992-03-02 CA CA 2101074 patent/CA2101074A1/en not_active Abandoned
- 1992-03-02 AU AU13749/92A patent/AU1374992A/en not_active Abandoned
- 1992-03-02 EP EP19920906574 patent/EP0573540A1/en not_active Ceased
- 1992-03-02 JP JP4505933A patent/JPH06504676A/en active Pending
- 1992-03-02 WO PCT/DK1992/000064 patent/WO1992015695A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0197794A2 (en) * | 1985-04-08 | 1986-10-15 | Sankyo Company Limited | Preparation of peptides with C-terminal proline amide |
US4652627A (en) * | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
US4687839A (en) * | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
EP0308067A2 (en) * | 1987-08-14 | 1989-03-22 | Unigene Laboratories Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
WO1990008194A1 (en) * | 1989-01-17 | 1990-07-26 | Suntory Limited | PROCESS FOR PRODUCTION OF C-TERMINAL α-AMIDATED PEPTIDE |
Non-Patent Citations (2)
Title |
---|
Carlsberg Res. Commun., Vol. 46, 1981, KLAUS BREDDAM et al., "Carboxypeptidase Y catalyzed C-terminal modifications of peptides", see page 121 - page 128. * |
CHEMICAL ABSTRACTS, Volume 107, No. 21, 23 November 1987, (Columbus, Ohio, US), TAMAOKI, HIDETSUNE et al.: "C-terminal amidation of synthetic model substrates of human calcitonin by carboxypeptidase Y", see page 358, Abstract 193853q, & Sankyo Kenkyusho Nempo 1986, 38, 73-79. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10047857A1 (en) * | 2000-09-27 | 2002-04-18 | Univ Leipzig | Process for the selective biocatalytic modification of peptides and proteins |
DE10047857B4 (en) * | 2000-09-27 | 2004-11-18 | Universität Leipzig | Process for the selective biocatalytic modification of peptides and proteins |
US10053491B2 (en) | 2013-11-05 | 2018-08-21 | Ajinomoto Co., Inc. | Method for producing peptide hydrazide, peptide amide, and peptide thioester |
Also Published As
Publication number | Publication date |
---|---|
DK67691D0 (en) | 1991-04-15 |
JPH06504676A (en) | 1994-06-02 |
IE920664A1 (en) | 1992-09-09 |
CA2101074A1 (en) | 1992-09-02 |
AU1374992A (en) | 1992-10-06 |
EP0573540A1 (en) | 1993-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6339237B2 (en) | ||
US4645740A (en) | Process for enzymatic replacement of the B-30 amino acid in insulins | |
US5032675A (en) | Process for the production of glutamine derivatives | |
AU660944B2 (en) | Process for the preparation of C-terminally amidated peptides | |
JPH0570433B2 (en) | ||
US5580751A (en) | Process for the preparation of C-terminally amidated peptides | |
CA1195940A (en) | Process for enzymatic replacement of the b-30 amino acid in insulins | |
WO1992015695A1 (en) | Process for the c-terminal modification of peptides having a c_terminal penultimate proline residue | |
US20070106063A1 (en) | Method for extracting insulins by improved air-gassing of a folding | |
US5252705A (en) | Peptide derivatives | |
CA1046441A (en) | Peptide synthesis using pepsin | |
GB2220938A (en) | Use of PAM enzyme in solid phase peptide synthesis | |
JP2777193B2 (en) | Method for producing peptide | |
EP0570244B1 (en) | Process for preparing peptides having a C-terminal proline amide | |
DE2647188C2 (en) | Process for the production of oligopeptides | |
EP2167673B1 (en) | Process for the conversion of c-terminal peptide esters or acids to amides employing subtilisin in the presence of ammonium salts | |
AU647796B2 (en) | An enzymatic process for the preparation of derivatives of growth hormone releasing factor and peptides useful as intermediates in the process | |
EP0277561A1 (en) | New arginine derivative, process for the preparation thereof and its use in peptide synthesis | |
CN115433266A (en) | Solid-phase synthesis method of teriparatide | |
Bodenmuller | Isolation and structural analysis of a new neuropeptide, the head activator | |
JPH05336987A (en) | Enzymatic peptide synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992906574 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2101074 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1993 108742 Country of ref document: US Date of ref document: 19930901 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1992906574 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 1992906574 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992906574 Country of ref document: EP |